Medical Device | June 30, 2022
NADMED brings first CE-marked NAD+ analysis kit to the market
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
It is a two dose vaccine to be administered intramuscularly at 28 days apart
LoveDepot.com addresses this gap that is yawning in the market
We must try to make the health care system more accessible for people with disabilities
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
The settlement and dismissal resolves all claims between the parties
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Subscribe To Our Newsletter & Stay Updated
